Introduction {#S1}
============

Despite worldwide reduction in childhood mortality, sepsis remains one of the leading causes of childhood deaths. Importantly, 35--50% of pediatric sepsis deaths occur in previously healthy children ([@B1]--[@B3]). These children often develop non-specific symptoms suggestive of a viral respiratory infection, followed by sudden deterioration and rapid progression to shock and multisystem organ failure. In addition to pathogen virulence factors, such as streptococcal Toxic Shock Toxin ([@B4]), rare genetic variants causing a primary immunodeficiency (PID) may underlie fulminant sepsis. Such variants have high effect sizes and are usually kept at low frequencies in the population due to purifying selection ([@B5], [@B6]). Previous studies searching for PID in children with bacterial sepsis were limited to conventional immunological testing ([@B5]). Using high-throughput sequencing studies on individuals with extreme phenotypes, who are most likely to be informative from a genetic point of view, has been demonstrated to be very powerful in Mendelian diseases but has not been reported in patient cohorts with invasive bacterial infections ([@B6]).

*Pseudomonas aeruginosa* (*P. aeruginosa*) is an aerobic Gram-negative bacterium commonly found in environment. This opportunistic pathogen causes invasive infections in immunosuppressed and hospitalized patients and represents a major cause of health care-related infections. In contrast, sepsis due to community-acquired *P. aeruginosa* is extremely rare in apparently healthy children, and carries very high mortality ([@B7], [@B8]), and may be the first manifestation of an underlying PID. Indeed, a few case reports have already described the identification of PIDs in children with *P. aeruginosa* sepsis ([@B9], [@B10]). Here, we used exome sequencing and bioinformatic analysis to identify genetic variants conferring extreme susceptibility to *P. aeruginosa* in a cohort of 11 previously healthy children.

Materials and Methods {#S2}
=====================

Patients {#S2-1}
--------

Children below 60 months with community-acquired blood-culture positive *P. aeruginosa* sepsis were eligible. Children with any comorbidities (prematurity, congenital malformations, previous surgery, immunosuppression, known immunodeficiency, and chronic diseases) and children who had been exposed to broad-spectrum intravenous antibiotics were excluded. This study was carried out in accordance with the recommendations of the ethics committees of participating centers (Kantonale Ethikkommission Bern, KEK Ref Nr 029/11, Bern, Switzerland; Mater Health Services HREC13/MHS/4, Brisbane, QLD, Australia). Parents/guardians of all included patients gave written informed consent in accordance with the Declaration of Helsinki. Patients were recruited prospectively and retrospectively in hospital databases and infectious diseases networks. Whenever possible, DNA was also collected from the parents.

DNA Extraction and Exome Sequencing {#S2-2}
-----------------------------------

Genomic DNA was extracted from whole blood (*N* = 8), frozen skin biopsy or lymphatic tissue (*N* = 2), or paraffin-fixed histology slides (*N* = 1). Exome sequencing libraries were prepared using Agilent SureSelect (V5, 50.4 Mb). Cluster generation was performed using Illumina TruSeq PE Cluster Kit v5 reagents. Libraries were sequenced as 100 bp long, paired-end reads on Illumina HiSeq 2500 using TruSeq SBS Kit v5 reagents.

Short Read Alignment {#S2-3}
--------------------

Sequencing reads were processed using CASAVA v1.82. Reads were aligned to the human reference genome hg19 using BWA ([@B11], [@B12]) v0.6.2. PCR duplicates were removed using Picard 1.27-1 (<http://picard.sourceforge.net/>).

Variant Calling {#S2-4}
---------------

We used genome analysis toolkit (GATK) ([@B13], [@B14]) version 3.1-1 to call single nucleotide variants (SNVs) and small insertion and deletions (indels) from duplicate-marked bam files. We used HaplotypeCaller for multi-sample variant calling on all samples followed by GATK best practice to call the variants and included only variants that were flagged as PASS by GATK in subsequent analysis.

Variant Effect Prediction {#S2-5}
-------------------------

We used SnpEff ([@B15]) version 4.1B to predict the functional impact of variants. As variants can have several predicted effects, we only considered the most severe effect for each variant. The effects in decreasing order of severity are frameshift and in-frame for indels and stop-gain, splice site-disrupting, non-synonymous, synonymous, intronic, UTR, non-coding exon, and intergenic for SNVs. Variants were annotated as putative loss-of-function (LoF) if they were stop-gain or splice site-disrupting SNVs or frameshift indels mapping to the first 95% of coding region, or larger deletions removing either the first exon or more than 50% of the protein-coding sequence of the affected transcript.

Variant Frequency Estimation {#S2-6}
----------------------------

We checked the minor allele frequency (MAF) of all previously described variants in the following datasets: the NHLBI exome sequencing project (ESP, *N* = 6503) ([@B16]), the 1000 genomes project phase 2 (1KG, *N* = 876) ([@B17]) and the UK10K project (UK10K, *N* = 3621) ([@B18]), the Exome Aggregation Consortium database (ExAC, *N* = 60,706) ([@B19]), and a set of 533 in-house control exomes.

Identification of Potentially Causal Variants in Parent--Child Trios {#S2-7}
--------------------------------------------------------------------

We restricted analyses to non-synonymous and LoF exonic variants with MAF \<1% in ESP, 1KG, UK10K, ExAC, and in-house control exomes. We analyzed each family separately assuming autosomal recessive, autosomal dominant, and X-linked recessive inheritance models. Only variants with \>10× coverage in both the parents and the offspring were included in the *de novo* analysis. We assumed full penetrance for the potentially causal variants and given the fatality of the phenotype did not consider a mutation as potentially causal if it was present in the parents, any of the abovementioned databases or in the in-house control exomes in the same zygosity form (i.e., heterozygous or homozygous) as in our patients.

Identification of Potentially Causal Variants in Individual Patients {#S2-8}
--------------------------------------------------------------------

We restricted analyses to non-synonymous and LoF exonic variants with MAF \<1% in ESP, 1KG, UK10K, ExAC, and in-house control exomes. We analyzed each individual separately assuming autosomal recessive and X-linked recessive inheritance models. We assumed full penetrance for the potentially causal variants and given the fatality of the phenotype did not consider a mutation as potentially causal if it was present in any of the abovementioned databases or in the in-house control exomes in the same zygosity form (i.e., heterozygous or homozygous) as in our patients.

Targeted Search in Primary Immunodeficiency Genes {#S2-9}
-------------------------------------------------

We ran a targeted search for rare (MAF \<1%), non-synonymous, and LoF variants in a list of 252 known PID genes. This list includes known genes in 50 PID syndromes compiled by The International Union of Immunological Societies (IUIS) Expert Committee in 2015 ([@B20]) and 3 newly published PID genes since the latest release of IUIS till April 2016 (Table [1](#T1){ref-type="table"}).

###### 

**New PID genes discovered since the latest report of IUIS in 2015 till April 2016**.

  Official gene name   Mutation    Inh.   Phenotype                                                                  Study population              Reference
  -------------------- ----------- ------ -------------------------------------------------------------------------- ----------------------------- -----------
  STAT4                Missense    AD     Kaposi sarcoma                                                             One consanguineous pedigree   ([@B21])
  MAP3K9               Non-sense   AR     Susceptibility to severe bacterial infection, *Pseudomonas* septic shock   One consanguineous pedigree   ([@B22])
  IRF3                 Missense    AD     Herpes simplex encephalitis                                                16 sporadic cases             ([@B23])

*AR, autosomal recessive; AD, autosomal dominant; Inh., inheritance; GOF, gain-of-function*.

Gene-Annotation Enrichment Analysis {#S2-10}
-----------------------------------

We used the database for annotation, visualization, and integrated discovery (DAVID) ([@B24], [@B25]) v6.7 with default options and highest classification stringency for functional annotation clustering of PID genes carrying rare, non-synonymous variants. We used hypergeometric test for assessing the significance of gene enrichment results.

C9 Reconstitution Experiment {#S2-11}
----------------------------

Serum of a patient heterozygous for a complement *C9* variant was diluted with GVB^++^ in a series starting at 1:10 to 1:640 in 1:2 steps. The same was done with a serum pool as a control. This pool consisted of serum from over 300 healthy donors. Forty microliters of these dilutions were pipetted in duplo in a round-bottom 96-wells plate. To these wells, 40 μl of GVB^++^ was added to the samples and the blanc, to the positive control 40 μl of 1.7% saponin was added (100% lysis). Ten microliters of purified C9 (Quidel) or GVB^++^ were added (end conc 50 μg/ml). Next, in all wells, 150 μl of EA's were added. EA's are sheep erythrocytes (Hatunalab, Sweden) coated with an optimal dose of Amboceptor (Rabbit-anti-Sheep erythrocyte; Dade Behring) brought to a concentration of 0.25 × 10^8^ cells/ml. This was incubated for 1 h at 37°C while agitating. After incubation, the plate was centrifuged for 5 min at 2000 rpm. Fifty microliters of each supernatant were pipetted to a flat-bottom 96-wells plate and diluted with 150 μl GVB^++^. Extinction was measured at 415 nm using a spectrophotometer. The percentage of lysis was calculated as follows: $$\left( \left( {\textit{average~of~sample~duplo} - \textit{average~blanc}} \right)/{\left( \left. \textit{average~}100\% - \textit{average~blanc} \right) \right) \times 100.} \right.$$

GVB^++^ buffer consisted of 2 mM 5,5 di-ethylbarbituurzuur (Genfarma), 1.15 mM Na 5,5 di-ethylbarbituraat (Bufa), 96 mM NaCl (Merck), 0.5 mM CaCl (Merck), and 0.18 mM MgCl~2~ (Merck).

Results {#S3}
=======

Clinical Presentation {#S3-1}
---------------------

We identified 11 previously healthy children with community-acquired *P. aeruginosa* bacteremia from whom DNA could be obtained. Child--parent DNA trios were available in seven affected families. The presenting age ranged from 6 months to 4 years, and 7/11 (64%) of patients were male (Table [2](#T2){ref-type="table"}). All patients had never been admitted to hospital or exposed to intravenous antibiotics prior to presenting with *P. aeruginosa* sepsis. Nine patients had developed respiratory symptoms within 72 h of leading to hospital admission, one presented with Ecthyma gangrenosum (Figure [1](#F1){ref-type="fig"}), and eight (73%) died. Three children died in the emergency department shortly after presentation, and all deaths occurred within 48 h of hospital admission. Postmortem examination reports were available in seven cases. In four, *P. aeruginosa* grew in high quantities from nasal and oral swabs, tracheal secretions, and lungs. Viral co-infections were found in five deceased patients, including human herpes virus-6, parainfluenza virus-3, human metapneumovirus, respiratory syncytial virus, and varicella virus. One surviving patient presented with acute abdomen, and *P. aeruginosa* bacteremia was thought to result from intra-abdominal perforation. Another surviving patient was diagnosed with urosepsis and *P. aeruginosa* grew in urine and blood. The third surviving patient presented with recurrent parainfectious neutropenia. Six patients received aminoglycosides and/or anti-*Pseudomonas* beta-lactam antibiotics during sepsis, including all three survivors.

###### 

**Demographic and clinical characteristics of included children with community-acquired *Pseudomonas aeruginosa* septicemia**.

  Patient   DNA source        Phenotype   Parental DNA available   Ethnicity        Age (mo.)   Sex   Consanguinity   Viral co-infection   WCC    CRP   Clinical focus         Previous history
  --------- ----------------- ----------- ------------------------ ---------------- ----------- ----- --------------- -------------------- ------ ----- ---------------------- --------------------------------------------
  S1        Blood             Fatal       Yes                      Caucasian        24          M     No              Parainflue nza 3     1.2    136   Pneumonia              Recurrent middle ear infections
  S4        Blood             Fatal       Yes                      Caucasian        13          M     No              HHV-6                0.6    NA    Septic shock           Recurrent middle ear infections
  S7        Blood             Fatal       Yes                      Caucasian        9           F     No              Parainflue nza 3     1.3    46    Ecthyma gangraenosum   Nil
  S10       Blood             Survived    Yes                      South American   8           M     No              None                 2      132   Acute abdomen          Nil
  S13       Blood             Fatal       No                       Asian            26          M     Yes             Varicella            2.4    36    Septic shock           Recurrent respiratory infections
  S14       Lymph node        Fatal       No                       African          31          F     No              None                 1      NA    Pneumonia              Nil
  S15       Blood             Survived    No                       Caucasian        56          M     No              None                 26.9   235   Urosepsis              Nil
  S16       Blood             Survived    No                       Caucasian        7           M     No              None                 1.2    301   Septic shock           Recurrent infection-associated neutropenia
  S17       Fibroblasts       Fatal       Yes                      Asian            9           M     No              hMPV, RSV            0.8    NA    Septic shock           Nil
  S20       Paraffin slides   Fatal       Yes                      Caucasian        30          M     No              None                 1.2    213   Pneumonia              Recurrent respiratory infections
  S23       Blood             Fatal       Yes                      Asian            26          M     No              None                 1.6    157   Septic shock           Recurrent respiratory infections

*F, female; M, male; mo, months old; CRP, C-reactive protein; WCC, white cell count (×10^9^/l)*.

![**Ecthyma gangrenosum, a highly suggestive rapidly progressive purpuric skin lesion seen in a minority of children with *P. aeruginosa* bacteremia, is shown in one of the study patients (with permission from parents)**.](fimmu-07-00357-g001){#F1}

Exome Sequencing and Short Read Alignment {#S3-2}
-----------------------------------------

For each sample, 95% of reads passing filtering criteria were unique (not marked as duplicate); 97% of unique reads could be aligned to the human reference genome hg19. The mean on-bait coverage was 66×, with 95% of target bases achieving at least 10× coverage and 76% achieving at least 30× coverage (Table S1 in Supplementary Material). In 118 of the PID genes, at least one exon had an average coverage of \<2×. Further investigation of these low-coverage intervals showed that the majority of them are overlapping with untranslated regions (UTRs).

Variant Calling and Variant Annotation {#S3-3}
--------------------------------------

A total of 115,604 SNVs and 10,814 indels passed GATK quality control, including 28,795 synonymous variants, 28,284 non-synonymous variants, 713 in-frame indels, 660 frameshift indels, 283 stop-gained, and 151 splice-site variants (Tables S2 and S3 in Supplementary Material).

Variant Analysis {#S3-4}
----------------

Thirty-eight rare, non-synonymous coding variants (MAF \<1%) were observed in the 11 patients after testing for different inheritance models (Table [3](#T3){ref-type="table"}), among which 12 were never seen in the same zygosity form (heterozygous or homozygous) in publicly available databases (Table [4](#T4){ref-type="table"}). In addition to the above 38 variants, we performed a targeted search for rare, non-synonymous coding variants in 252 previously known PID genes and found 76 variants in 61 genes (Table [5](#T5){ref-type="table"}). Functional classification of these 61 genes using DAVID highlighted the complement pathway as the most enriched cluster (DAVID enrichment score: 15.73). In total, 14 of the 28 complement pathway genes present in the list of 252 known PID genes carried at least one rare, non-synonymous coding variant in our cohort (hypergeometric probability: *p*(*x* \> 14) = 0.003).

###### 

**38 rare (MAF \<1% in ESP, 1KP, UK10K, ExAC, and in-house controls) non-synonymous and putative LoF variants found in our 11 patients using different inheritance models (see [Materials and Methods](#S2){ref-type="sec"} for details)**.

  Patient     Inheritance           Chr    Position    Effect                   Gene         ExAC MAF%
  ----------- --------------------- ------ ----------- ------------------------ ------------ -----------
  S4          AR                    2      202957848   Missense                 AC079354.1   0.33
  S4          XL                    X      99920649    Missense                 SRPX2        0
  S4          XL                    X      100617192   Frameshift               BTK          0
  S10         AD                    13     112721975   Missense, *de novo*      SOX1         0
  S10         AR                    10     71906005    Missense                 TYSND1       0.37
  S10         XL                    X      9864517     Missense                 SHROOM2      0
  S10         XL                    X      53575033    Missense                 HUWE1        0
  S10         XL                    X      70824419    Missense                 ACRC         0
  S13         AR                    19     55879673    Missense                 IL11         0.01
  S13         AR                    19     56423631    Missense                 NLRP13       0.01
  S13         AR                    19     57132935    Missense                 ZNF71        0
  S13         AR                    19     57840274    Missense                 ZNF543       0.01
  S13         AR                    20     31765978    Missense                 BPIFA2       0.02
  S13         AR                    20     31393172    In-frame indel           DNMT3B       0
  S13         XL                    X      53222222    Missense                 KDM5C        1.41E−03
  S13         XL                    X      101619974   Missense                 NXF2B        0
  S14         AR                    3      119526149   Missense                 NR1I2        0.14
  S14         AR                    3      19977627    Splice site disrupting   EFHB         0.29
  S14         AR                    17     1265305     splice site disrupting   YWHAE        0.03
  S14         AR                    19     39362359    splice site disrupting   RINL         0.15
  S15         XL                    X      27998602    Missense                 DCAF8L1      0.01
  S15         XL                    X      68382133    Missense                 PJA1         0
  S15         XL                    X      101097713   Splice site disrupting   NXF5         0
  S17         AR                    1      6662288     Missense                 KLHL21       0.16
  S17         CH                    1      155015918   Missense                 DCST1        0.26
  155015948   Missense              0                                                        
  S17         CH                    10     112572308   Missense                 RBM20        0.01
  112590912   Missense              0.02                                                     
  S17         CH                    17     76420087    Missense                 DNAH17       0.01
  76522984    Missense              0.03                                                     
  S17         XL                    X      109561080   Missense                 AMMECR1      0
  S20         CH                    19     41035017    Missense                 SPTBN4       0.08
  41025445    Missense, *de novo*   0                                                        
  S23         CH                    16     4934707     Missense                 PPL          8.23E−04
  4940241     Missense              0.05                                                     
  S23         CH                    17     28405505    Missense                 EFCAB5       0.05
  28380755    Non-sense             0.01                                                     
  S23         XL                    X      19364694    Missense                 PDHA1        0.29

*Chr, chromosome; AR, autosomal recessive; AD, autosomal dominant, XL, X-linked; CH, compound heterozygous*.

###### 

**Potentially causal variants (see [Materials and Methods](#S2){ref-type="sec"} for details) identified in 6 of the 11 previously healthy children with community-acquired *Pseudomonas aeruginosa* septicemia**.

  Inheritance   Patient   Chr.        Position    Gene                     Effect                ExAC MAF (%)
  ------------- --------- ----------- ----------- ------------------------ --------------------- --------------
  AR            S14       7           142562052   EPHB6                    In-frame indel        0
  S13           20        31393172    DNMT3B      In-frame indel           0                     
                                                                                                 
  AD            S20       19          41025445    SPTBN4                   Missense, *de novo*   0
  S10           13        112721975   SOX1        Missense, *de novo*      0                     
                                                                                                 
  XL            S4        X           100617192   BTK                      Frameshift indel      0
  S10           X         27998602    DCAF8L1     Missense                 1.14E−03              
  S10           X         9864517     SHROOM2     Missense                 0                     
  S10           X         53575033    HUWE1       Missense                 0                     
  S10           X         70824419    ACRC        Missense                 0                     
  S15           X         68382133    PJA1        Missense                 0                     
  S15           X         101097713   NXF5        Splice site disrupting   0                     
  S15           X         109561080   AMMECR1     Missense                 0                     

*Chr, chromosome; MAF, minor allele frequency; AR, autosomal recessive; AD, autosomal dominant, XL, X-linked*.

###### 

**76 rare (ExAC MAF \<1%) non-synonymous and putative LoF variants found in known 252 PID genes in our 11 patients**.

  Patient   Chr.   Position    Effect                Type   Gene      ExAC MAF%
  --------- ------ ----------- --------------------- ------ --------- -----------
  S1        11     108098576   Missense              Het    ATM       0.74
  S10       9      340168      Missense              Het    DOCK8     0
  S10       11     4104647     Missense              Het    STIM1     8.25E−04
  S10       11     108117787   Missense              Het    ATM       0.13
  S10       5      41155088    Missense              Het    \*C6      0.69
  S13       20     31393172    In-frame indel        Hom    DNMT3B    0
  S13       8      100844596   Splice site disrupt   Het    VPS13B    0.43
  S13       2      231036831   Missense              Het    SP110     4.12E−03
  S13       5      77334907    Missense              Het    AP3B1     0.08
  S13       6      31915584    Missense              Het    \*CFB     0.1
  S13       11     6637588     Missense              Het    TPP1      0.18
  S13       11     2407334     Missense              Het    CD81      0.56
  S13       5      147475388   Missense              Het    SPINK5    0.65
  S13       5      35876300    Missense              Het    IL7R      0.24
  S13       12     110034347   Missense              Hom    MVK       0.13
  S13       1      196799796   Missense              Hom    \*CFHR1   0.14
  S13       10     6063567     Missense              Het    IL2RA     0.88
  S14       8      100654621   Missense              Het    VPS13B    0.02
  S14       12     110017618   Missense              Het    MVK       0.07
  S14       8      100861113   Missense              Het    VPS13B    0.06
  S14       1      11094908    Missense              Het    \*MASP2   0.08
  S14       15     91337505    Missense              Het    BLM       0.1
  S14       8      48733399    Missense              Het    PRKDC     0.09
  S14       6      32798457    Missense              Het    TAP2      0.49
  S14       1      949422      Missense              Het    ISG15     0.16
  S14       11     108129778   Missense              Het    ATM       0.21
  S14       11     108123551   Missense              Het    ATM       0.29
  S14       3      196198925   Missense              Het    RNF168    0.2
  S14       8      90982691    Missense              Het    NBN       0.26
  S14       9      139840153   Missense              Het    \*C8G     0.46
  S14       4      187004767   Missense              Het    TLR3      0.3
  S14       6      32800427    Missense              Het    TAP2      0.61
  S14       1      196684855   Missense              Het    \*CFH     0.5
  S14       10     73103969    Missense              Het    SLC29A3   0.54
  S14       9      123751873   Missense              Het    \*C5      0.61
  S14       9      123737145   Missense              Het    \*C5      0.91
  S14       1      196715063   Missense              Het    \*CFH     0.97
  S14       20     62324328    Missense              Het    RTEL1     0.98
  S15       5      39342214    Non-sense             Het    \*C9      0.1
  S15       2      47277182    Missense              Het    TTC7A     0.2
  S15       2      47273468    Missense              Het    TTC7A     0.21
  S15       10     97983635    Missense              Het    BLNK      0.55
  S15       11     108138003   Missense              Het    ATM       0.91
  S16       16     27460420    Missense              Het    IL21R     0.03
  S16       9      139264888   Missense              Het    CARD9     0.35
  S16       5      158750329   Missense              Het    IL12B     0.65
  S17       17     73826517    Missense              Het    UNC13D    2.25E−03
  S17       1      949431      Missense              Het    ISG15     4.17E−03
  S17       16     50745960    Missense              Het    NOD2      0.03
  S17       5      1268697     Missense              Het    TERT      0.09
  S17       17     26875685    Missense              Het    UNC119    0.01
  S17       17     76120792    Missense              Het    TMC6      0.65
  S17       15     91295110    Missense              Hom    BLM       0.86
  S17       8      42177163    Missense              Het    IKBKB     0.89
  S20       11     118898444   Missense              Het    SLC37A4   0
  S20       12     122064747   Missense              Het    ORAI1     0
  S20       22     36662063    Missense              Het    APOL1     0.01
  S20       1      22965341    Missense              Het    \*C1QA    0.04
  S20       11     108119823   Missense              Het    ATM       0.22
  S20       4      151242409   Missense              Het    LRBA      0.46
  S23       1      207646266   Missense              Het    \*CR2     3.30E−03
  S23       1      235896980   Missense              Het    LYST      0.02
  S23       1      154247666   Missense              Het    HAhet     0.03
  S23       1      183536358   Missense              Het    NCF2      0.23
  S23       6      137540425   Missense              Het    IFNGR1    0.14
  S23       22     31007023    Missense              Het    TCN2      0.27
  S23       1      207925595   Missense              Het    \*CD46    0.5
  S23       5      40945397    Missense              Het    \*C7      0.95
  S4        X      100617192   Frameshift indel      Het    BTK       0
  S4        1      151316324   Missense              Het    RFX5      0.88
  S7        12     133263886   Missense              Het    POLE      0.14
  S7        19     18170874    Missense              Het    IL12RB1   0.17
  S7        X      77150892    Missense              Het    MAGT1     0.29
  S7        16     81957106    Missense              Het    PLCG2     0.13
  S7        4      110667485   Missense              Het    \*CFI     0.34
  S7        5      41155088    Missense              Het    \*C6      0.69

*The genes marked by the asterisk are involved in complement activation*.

*Chr, chromosome; hom, homozygous; het, heterozygous*.

In one patient (patient S4) who died of fulminant septic shock, we identified a novel single-base insertion on the X chromosome (C \> CT, chromosome 20, position 100617191) leading to a frameshift in the Bruton agammaglobulinemia tyrosine kinase (*BTK*) gene. Other than a middle ear infection during infancy, the previous history, growth, development, and vaccination history of the patient had been unremarkable. Taqman genotyping and clinical genetic testing confirmed presence of mutation in the deceased patient and revealed a *de novo* occurrence in the mother, while other family members were healthy. BTK plays a crucial role in B-cell development. Postmortem serological testing confirmed the absence of immunoglobulins, consistent with BTK LoF: IgG \< 1.3 g/l (4.22--11.9); IgA \< 0.2 g/l (0.2--1.58); IgM \< 0.2g/l (0.48--1.9).

A novel homozygous deletion spanning 6 bp on chromosome 20 (ACTCGAG \> A, X chromosome, position 31393171) was observed in a 2-year-old boy with consanguineous parents (patient S13), leading to an in-frame deletion in a conserved region of the catalytic domain of the *DNMT3B* gene. Previously described missense mutations in the same protein domain are known to cause immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome ([@B26]), a rare disease characterized by variable immunodeficiency and recurrent infections with mild facial abnormalities. The fatal septicemia was preceded by uncomplicated varicella, and the patient had a history of recurrent mild respiratory and upper airway infections that had been attributed to poor health conditions. The patient had normal T and B cell counts but reduced immunoglobulin levels, consistent with ICF syndrome: IgG 0.16 g/l (4.22--11.9); IgA \<0.06 g/l (0.2--1.58); IgM 0.05 g/l (0.48--1.9).

We also observed a rare, known (MAF = 0.001 in ExAC) heterozygous stop-gain variant in the complement *C9*, on chromosome 5 (G \> T, chromosome 5, position 39342214) in a male patient (patient S15) with severe *Pseudomonas* septicemia and recurrent parainfectious neutropenia. The patient survived without sequelae. Complement reconstitution assay with classical or terminal pathway proteins (C1--C9) showed normal lytic activity (Figure [2](#F2){ref-type="fig"}), suggesting that this variant is unlikely to be causal to increased susceptibility to *P. aeruginosa*.

![**Titration of serum with/without C9 in a study patient with a heterozygous stop-gain variant in the *C9* gene**.](fimmu-07-00357-g002){#F2}

Discussion {#S4}
==========

We studied *P. aeruginosa* sepsis in previously healthy children as a model disease defining an extreme phenotype of fulminant sepsis. Fulminant sepsis in children is associated with high mortality, and the majority of deaths occur within hours of presentation ([@B27]). The disease burden is highest in children under 5 years of age ([@B3], [@B7]). We hypothesized that rare genetic variants with high effect sizes could explain life-threatening susceptibility to *P. aeruginosa* in children without known risk factors or comorbidities. Mendelian disorders of immunity have previously been shown to result in phenotypes with unusual susceptibility to bacterial infection, such as pseudomonal and pneumococcal infections in patients with IRAK-4 deficiency ([@B10], [@B28]). We used exome sequencing to explore the genetic cause of susceptibility to *P. aeruginosa* in a carefully selected group of previously healthy children with no familial history of immunodeficiency, who developed community-acquired *P. aeruginosa* septicemia. By systematic search for fully penetrant, rare, non-synonymous, and LoF variants in exonic regions, we identified 12 potentially causal variants including two novel variants in known PID genes: X-linked agammaglobulinemia due to a novel *BTK* mutation and ICF immunodeficiency syndrome due to a novel *DNMT3B* mutation. In addition, we performed a targeted search for rare, non-synonymous, and LoF variants in known PID genes and observed an enrichment of such variants among genes that are part of the complement pathway. One patient carried a heterozygous, stop-gain variant in the *C9* gene, which has been associated with recurrent meningitis ([@B29], [@B30]). However, functional testing of patient samples showed normal lytic activity, demonstrating the need for strict validation of potentially causal mutations, even in genes with plausible biological links to the study phenotype. Variants conferring life-threatening susceptibility to common infections in children below reproductive age are subjected to strong purifying selection and will therefore only be found at very low frequencies ([@B31]--[@B33]). Out of the 12 potentially causal variants described in this study, 11 were novel and 1 was a hemizygous variant present in 1 individual (in heterozygous form) in ExAC.

Previous case reports describing *P. aeruginosa* sepsis in children with known PIDs, such as Wiskott--Aldrich syndrome, X-linked agammaglobulinemia, cyclic neutropenia, and IRAK-4/MyD-88 deficiency ([@B8], [@B10], [@B22], [@B34]), were based on conventional, candidate--gene-driven immunological testing. Ecthyma gangrenosum is present in a minority of patients and has been described as the presenting sign of an underlying PID, such as cyclic neutropenia, chronic granulomatous disease, or hypogammaglobulinemia ([@B35]--[@B37]). The range of PID types identified in these previous reports indicates that multiple distinct genetic defects have to be considered when investigating such clinical presentations. Importantly, classic PID screening may fail to identify new mutations in known PID genes ([@B38]) and will miss causal mutations in genes without an established link with PIDs. Failure to diagnose rare underlying PID in a child presenting with sepsis may result in potentially devastating consequences for survivors, undiagnosed siblings, and their families. High-throughput sequencing, in particular exome sequencing, has proved highly successful in the clinical diagnosis of suspected monogenic conditions in the pediatric population ([@B39]--[@B41]). This was recently illustrated by Record et al., who used exome sequencing in a girl with *P. aeruginosa* sepsis and found a homozygous LoF mutation in *MAP3K9* (*MKL1*), a gene that was not known to cause PID ([@B22]).

A strength of the present cohort is that the case definition required significant growth of community-acquired *P. aeruginosa* in blood culture in previously healthy children presenting with signs and symptoms of sepsis, thereby constituting an extreme phenotype. The majority of children included in this study presented with fulminant sepsis and septic shock due to *Pseudomonas* sepsis. In the cases where postmortem examinations were performed, extensive growth of *P. aeruginosa* was found in several tissues, suggesting overwhelming bacterial infection. In agreement with other studies, we observed that several sepsis patients had viral co-infections ([@B3]). The role of viral co-infections in the pathogenesis of childhood bacterial sepsis is poorly understood and may include facilitated bacterial invasion due to respiratory epithelial disruption and increased host susceptibility during viremia ([@B42]). Immunological investigations in children presenting with fulminant sepsis can be extremely challenging, as severe leukopenia, coagulopathy, multi-organ failure, and fluid resuscitation often lead to severe alterations of cell counts, immunoglobulin levels, and complement levels. In addition, a proportion of patients die prior admission to an intensive care unit, or present with out-of-hospital cardiac arrest or sudden infant death syndrome ([@B43]). To date, there are no widely accepted guidelines to inform pediatricians, emergency and intensive care physicians, and pathologists about indications for specific immunological investigations in previously healthy children presenting with fulminant or fatal sepsis ([@B44]). Given the high fatality in our cohort, with several cases recruited considerable time after death of the patient, our study highlights the value of performing exome sequencing in this population using blood or tissue containing DNA. However, the lack of viable host cells in deceased patients may represent a major limitation toward functional validation of potentially causal variants. Elucidating the role of these variants in novel genes that may confer a PID phenotype will therefore require independent validation in other patients or cohorts.

While it is well known that PIDs can be responsible for severe bacterial infections, little is known about the proportion of children with invasive infections suffering from PID ([@B5]). In our cohort, defects in known PID genes were found in 25% of fatal cases. This is comparable to a recent study using exome sequencing in 50 patients with common variable immunodeficiency where exome sequencing identified disease-causing mutations in 30% of cases ([@B45]). While non-genetic factors, including variation in pathogen virulence and secondary neutropenia, may be responsible for the remaining cases, we cannot rule out that mutations in genes not previously associated with PID are at least partially involved. Sequencing of additional family members, sequencing of more cases with the same phenotype, and functional characterization of new candidate genes and variants will be required to identify such genetic factors. Furthermore, whole-genome sequencing is needed to explore the non-coding variants, large structural variants, and also exonic variants that are not be well-covered using exome sequencing.

In conclusion, this study provides proof of concept that exome sequencing allows the identification of rare genetic variants responsible for fulminant sepsis in children in whom immunodeficiency had not been previously suspected. Given the decreasing cost of exome and genome sequencing ([@B39], [@B40], [@B46]), we propose considering host DNA sequencing as a possible diagnostic procedure for apparently healthy children presenting with unusually severe or fatal sepsis.
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